Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 3/20 | 0.76 |
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | BCL6 | P41182 | 1/20 | 0.60 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448726 | 0.90 | TP53 (0.65) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL4215477 | 0.89 | TP53 (1.00) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL4212697 | 0.86 | KCNN3 (0.80) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL25199209 | 0.86 | TP53 (0.80) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL25193575 | 0.86 | KCNN3 (1.00) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL4219187 | 0.86 | TP53 (0.79) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL4218566 | 0.84 | LMNA (1.00) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL4210667 | 0.84 | BCL6 (0.64) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL25192044 | 0.83 | POLB (0.74) | TP53LMNAPOLBKCNN3NPSR1 | |
| SCHEMBL25190242 | 0.82 | KCNN3 (1.00) | TP53LMNAPOLBKCNN3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036475-A1 | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1863796-A1 | PYRAZOLYL-PYRIMIDINES AS POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006100212-A1 | PYRAZOLYL-PYRIMIDINES AS POTASSIUM CHANNEL MODULATING AGENTS AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036475-A1 | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use | KCND2, KCNJ2, KCNN3 | TP53 1721/4885LMNA 2922/4885POLB 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.